Teva Seeks Ban On Generic MS Drug Approvals By FDA
Teva Pharmaceutical Industries Ltd. urged a Washington, D.C., federal court on Thursday to bar the U.S. Food and Drug Administration from approving generic versions of its multiple sclerosis treatment Copaxone unless...To view the full article, register now.
Already a subscriber? Click here to view full article